Victim: FUJIFILM
Country : JP
Actor: sarcoma
Source:
Discovered: 2025-04-05 08:45:39.320157
Published: 2025-04-05 08:45:37.916134
Description :
Fujifilm, a prominent Japanese company, has become a victim of a ransomware attack attributed to the cybercriminal group Sarcoma. Despite this setback, Fujifilm continues to focus on advancing its research and development of liposome formulations, leveraging its sophisticated nano-dispersion and analysis technologies developed over years of diverse product innovation. The company ventured into clinical trials in the U.S. in 2017 with FF-10832, a liposome-based formulation designed to deliver the FDA-approved anti-cancer drug gemcitabine. In preclinical studies, both FF-10850 and FF-10832 showed promising results in extending survival periods when used in combination with immune checkpoint inhibitors. Furthermore, Fujifilm is exploring the applications of liposomes in conjunction with next-generation therapies, including nucleic acid and gene therapies. To support future growth and ensure a reliable supply of high-quality liposome formulations, the company is establishing a dedicated manufacturing facility for both investigational and commercial purposes through its subsidiary, FUJIFILM Toyama.
Country : JP
Actor: sarcoma
Source:
Discovered: 2025-04-05 08:45:39.320157
Published: 2025-04-05 08:45:37.916134
Description :
Fujifilm, a prominent Japanese company, has become a victim of a ransomware attack attributed to the cybercriminal group Sarcoma. Despite this setback, Fujifilm continues to focus on advancing its research and development of liposome formulations, leveraging its sophisticated nano-dispersion and analysis technologies developed over years of diverse product innovation. The company ventured into clinical trials in the U.S. in 2017 with FF-10832, a liposome-based formulation designed to deliver the FDA-approved anti-cancer drug gemcitabine. In preclinical studies, both FF-10850 and FF-10832 showed promising results in extending survival periods when used in combination with immune checkpoint inhibitors. Furthermore, Fujifilm is exploring the applications of liposomes in conjunction with next-generation therapies, including nucleic acid and gene therapies. To support future growth and ensure a reliable supply of high-quality liposome formulations, the company is establishing a dedicated manufacturing facility for both investigational and commercial purposes through its subsidiary, FUJIFILM Toyama.